Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in Breast Cancer

被引：9
作者：
Kwa M. [1 ]
Adams S. [1 ,2 ]
机构：
[1] New York University Langone Medical Center, New York, NY
[2] Laura and Isaac Perlmutter Cancer Center, New York University Langone Medical Center, 160 East 34th Street, New York, 10016, NY
来源：
Current Breast Cancer Reports | 2016年 / 8卷 / 1期
关键词：
Breast cancer; Immunotherapy; Translational research; Tumor-infiltrating lymphocytes;
D O I：
10.1007/s12609-016-0198-3
中图分类号：
学科分类号：
摘要：
Recent attention has focused on the antitumor immune response in breast cancer, in particular, the role of tumor-infiltrating lymphocytes (TILs). In certain breast cancer subtypes, the presence of TILs has prognostic value and is associated with clinical outcome and improved survival. The potential predictive value of TILs has also been investigated in regard to cytotoxic and antihuman epidermal growth factor receptor 2 (HER-2) therapies, but could also serve as a selection marker for novel immunotherapies. In this article, we review the current literature on TILs in breast cancer and discuss how TILs are emerging as a promising biomarker in mediating antitumor immunity. © 2016, Springer Science+Business Media New York.
引用
收藏
页码：1 / 13
页数：12
相关论文
共 71 条
[1]  
Moore O.S., Foote F.W., The relatively favorable prognosis of medullary carcinoma of the breast, Cancer, 2, 4, pp. 635-642, (1949)
[2]  
Demaria S.P.K., Adams S., Cross-talk of breast cancer cells with the immune system, Breast cancer: carcinogenesis, cell growth and signalling pathways. Rijeka, pp. 457-482, (2011)
[3]  
Oble D.A., Loewe R., Yu P., Mihm M.C., Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma, Cancer Immun, 9, (2009)
[4]  
Galon J., Costes A., Sanchez-Cabo F., Kirilovsky A., Mlecnik B., Lagorce-Pages C., Et al., Type, density, and location of immune cells within human colorectal tumors predict clinical outcome, Science, 313, 5795, pp. 1960-1964, (2006)
[5]  
Zhang L., Conejo-Garcia J.R., Katsaros D., Gimotty P.A., Massobrio M., Regnani G., Et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer, N Engl J Med, 348, 3, pp. 203-213, (2003)
[6]  
Denkert C., Loibl S., Noske A., Roller M., Muller B.M., Komor M., Et al., Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 1, pp. 105-113, (2010)
[7]  
Loi S., Sirtaine N., Piette F., Salgado R., Viale G., Van Eenoo F., Et al., Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02–98, J Clin Oncol, 31, 7, pp. 860-867, (2013)
[8]  
Mohammed Z.M., Going J.J., Edwards J., Elsberger B., McMillan D.C., The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer, Br J Cancer, 109, 6, pp. 1676-1684, (2013)
[9]  
Garcia-Martinez E., Gil G.L., Benito A.C., Gonzalez-Billalabeitia E., Conesa M.A., Garcia Garcia T., Et al., Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer, Breast Cancer Res, 16, 6, (2014)
[10]  
Ruffell B., Au A., Rugo H.S., Esserman L.J., Hwang E.S., Coussens L.M., Leukocyte composition of human breast cancer, Proc Natl Acad Sci U S A, 109, 8, pp. 2796-2801, (2012)
12345678